Mylan expands valsartan recall in US

By Flora Southey

- Last updated on GMT

(Image: Getty/ugurhan)
(Image: Getty/ugurhan)

Related tags Mylan contamination Carcinogen

Mylan has requested all lots of valsartan, as well as combination amlodipine/valsartan, and valsartan/ hydrochlorothiazide tablets, be returned in the US.

On November 20, Mylan Pharmaceuticals issued a voluntary nationwide recall​ of select lots of high blood pressure medicines, due to the presence of N-nitrosodiethylamine (NDEA) in the active pharmaceutical ingredient.

NDEA is classified by the International Agency for Research on Cancer​ as a probable carcinogen.

Yesterday, Mylan – which manufactures the API in Hyderabad, India – announced the contamination has prompted the firm to expand its nationwide recall, to now include all lots​ of valsartan tablets, amlodipine and valsartan tablets, and valsartan and hydrochlorothiazide tablets, within expiry.

The additional 104 lots were distributed in the US between March 2017 and November 2018, and are listed here​.

Mylan Laboratories Limited also manufactures valsartan for Teva Pharmaceuticals USA. Last month, the detection of NDEA in the latter’s valsartan-containing medicines prompted Teva to issue a voluntary recall​.

In Europe, authorities have similarly detected NDEA in some batches of Mylan’s valsartan API, and have suspended its use​ in medicines for the region.

Related news

Show more

Related products

show more

Increasing the Bioavailability of Oncology Drugs

Increasing the Bioavailability of Oncology Drugs

Content provided by Lonza Small Molecules | 13-Nov-2023 | White Paper

Oral tyrosine kinase inhibitors (TKIs) are a class of cancer drugs that can be highly susceptible to issues with solubility in the gastrointestinal tract

Efficient Freezing & Storage of Biopharmaceuticals

Efficient Freezing & Storage of Biopharmaceuticals

Content provided by Single Use Support | 06-Nov-2023 | White Paper

Various options exist for freezing biopharmaceutical bulk material, but selecting the most effective and efficient approach for each cold chain can be...

Manufacturing Drugs with Highly Potent APIs

Manufacturing Drugs with Highly Potent APIs

Content provided by Altasciences | 28-Sep-2023 | White Paper

In this issue of The Altascientist, we examine the critical considerations for the safe and compliant manufacture of drugs with highly potent APIs (HPAPIs),...

Follow us

Products

View more

Webinars